Li Kang Biomedical Co Ltd Total Liabilities
Li Kang Biomedical Co Ltd total liabilities. Based on the latest financial reports, Li Kang Biomedical Co Ltd (6242) has total liabilities worth NT$212.01 Million TWD (≈ $6.68 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Li Kang Biomedical Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Li Kang Biomedical Co Ltd (2002–2025)
Total liabilities of Li Kang Biomedical Co Ltd from 2002 to 2025. This chart illustrates how Li Kang Biomedical Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Li Kang Biomedical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Li Kang Biomedical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eva Live Inc. Common Stock
NASDAQ:GOAI
|
USA | $7.27 Million |
|
SJM Co Ltd
KO:123700
|
Korea | ₩55.88 Billion |
|
Communication & System Solution Public Company Limited
BK:CSS
|
Thailand | ฿1.22 Billion |
|
Hastings Technology Metals Ltd
AU:HAS
|
Australia | AU$137.26 Million |
|
Shaftesbury Capital PLC
LSE:SHC
|
UK | GBX1.04 Billion |
|
Bio-Works Technologies AB
ST:BIOWKS
|
Sweden | Skr21.55 Million |
|
Cipherlab Co Ltd
TWO:6160
|
Taiwan | NT$543.98 Million |
|
EVZ Ltd
AU:EVZ
|
Australia | AU$36.89 Million |
Liability Composition Analysis (2002–2025)
This chart breaks down Li Kang Biomedical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 6242 current and non-current assets.
Liquidity & Leverage Metrics
Li Kang Biomedical Co Ltd Total Liabilities Ratios Explained
Li Kang Biomedical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Li Kang Biomedical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Li Kang Biomedical Co Ltd (2002–2025)
The table below shows the annual total liabilities of Li Kang Biomedical Co Ltd from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$221.82 Million ≈ $6.99 Million |
+23.28% |
| 2024-12-31 | NT$179.93 Million ≈ $5.67 Million |
-8.65% |
| 2023-12-31 | NT$196.97 Million ≈ $6.21 Million |
+65.94% |
| 2022-12-31 | NT$118.70 Million ≈ $3.74 Million |
-4.33% |
| 2021-12-31 | NT$124.07 Million ≈ $3.91 Million |
-9.08% |
| 2020-12-31 | NT$136.46 Million ≈ $4.30 Million |
-4.57% |
| 2019-12-31 | NT$143.00 Million ≈ $4.51 Million |
+0.05% |
| 2018-12-31 | NT$142.93 Million ≈ $4.50 Million |
-4.95% |
| 2017-12-31 | NT$150.38 Million ≈ $4.74 Million |
-29.72% |
| 2016-12-31 | NT$213.96 Million ≈ $6.74 Million |
-13.18% |
| 2015-12-31 | NT$246.44 Million ≈ $7.76 Million |
+154.23% |
| 2014-12-31 | NT$96.93 Million ≈ $3.05 Million |
+10.78% |
| 2013-12-31 | NT$87.50 Million ≈ $2.76 Million |
+40.12% |
| 2012-12-31 | NT$62.45 Million ≈ $1.97 Million |
+5.18% |
| 2011-12-31 | NT$59.37 Million ≈ $1.87 Million |
+19.59% |
| 2010-12-31 | NT$49.65 Million ≈ $1.56 Million |
-60.07% |
| 2009-12-31 | NT$124.35 Million ≈ $3.92 Million |
-49.77% |
| 2008-12-31 | NT$247.58 Million ≈ $7.80 Million |
-14.72% |
| 2007-12-31 | NT$290.32 Million ≈ $9.15 Million |
-46.40% |
| 2006-12-31 | NT$541.69 Million ≈ $17.07 Million |
-4.57% |
| 2005-12-31 | NT$567.66 Million ≈ $17.88 Million |
+28.17% |
| 2004-12-31 | NT$442.91 Million ≈ $13.95 Million |
+2.50% |
| 2003-12-31 | NT$432.09 Million ≈ $13.61 Million |
+3.29% |
| 2002-12-31 | NT$418.31 Million ≈ $13.18 Million |
-- |
About Li Kang Biomedical Co Ltd
Li Kang Biomedical Co., Ltd. produces and sells pharmaceuticals, beauty products, and health food. It offers Chinese and Western medicines, nutritional supplements, beauty and skincare products, and daily necessities products. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014. Li Kang Biomedical Co., Ltd. was fou… Read more